Physician profile
Daniel Karpel
NPI 1134708324
$1,735.58
in general payments reported to CMS, 2019-2025
15 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $337 · 2023: $659 · 2024: $353 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $478.40 | 2022-2024 | Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $273.28 | 2023-2025 | Wainua, Fasenra |
| Actelion Pharmaceuticals US, INC. | $144.99 | 2025 | Opsumit, Uptravi |
| Abbvie INC. | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2024 | |
| Pfizer INC. | $120.73 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $117.76 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.00 | 2022 | |
| Glaxosmithkline, LLC. | $87.76 | 2023-2024 | Shingrix, Arexvy |
| Novo Nordisk INC | $36.21 | 2024 | Wegovy |
| Bridgebio Pharma, INC. | $32.16 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $30.36 | 2025 | Assure Wcd |
| Abiomed | $26.69 | 2025 | |
| Exact Sciences Corporation | $24.28 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.12 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Karpel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.